2018 Manufacturing Provider Relationship 
FDA Law Blog
SEPTEMBER 20, 2021
Torrente, explained in a previous post , in-person meetings create important opportunities for building rapport, and lead to more robust dialogue and collegial relationships between the Agency and sponsors. Livornese and Josephine M. The endpoints must be novel (i.e.
FDA Law Blog
MAY 26, 2025
Specifically, these are procedures and drugs used in providing what HHS had, until recently, referred to as gender-affirming care. Department of Health & Human Services purporting to provide a comprehensive review of the evidence and best practices for promoting the health of children and adolescents with gender dysphoria.
Expert insights. Personalized for you.
52 
Let's personalize your content